***E. coli, Salmonella* and *Campylobacter***

TEST FORMS

#### **TEST FORM – *E. coli***

Which method did you use for antimicrobial susceptibility testing of *E. coli* in this EQAS?

 [ ]  MIC - Broth microdilution

Which standard(s)/guideline(s) did you use when performing AST?

 [ ]  CLSI

 [ ]  EUCAST

 [ ]  ISO 20776-1:2019

 [ ]  TREK

Which incubation conditions did you use?      °C/     h

Which solvent was used for the preparation of the 0.5 McFarland solution

 [ ]  Water

 [ ]  Saline

 [ ]  Mueller Hinton broth

The inoculum was prepared by adding       µl of 0.5 McFarland solution in       mL CAMHB broth

What was the expected inoculum size?       \*       ^       CFU/mL (indicate for example 5 times 10 to the power of 5 using this format ‘5 \* 10 ^ 5’)

Comments or additional information:

#### **TEST FORM - *Salmonella***

Which method did you use for antimicrobial susceptibility testing of *Salmonella* in this EQAS?

 [ ]  MIC - Broth microdilution

Which standard(s)/guideline(s) did you use when performing AST?

 [ ]  CLSI

 [ ]  EUCAST

 [ ]  ISO 20776-1:2019

 [ ]  TREK

Which incubation conditions did you use?      °C/     h

Which solvent was used for the preparation of the 0.5 McFarland solution

 [ ]  Water

 [ ]  Saline

 [ ]  Mueller Hinton broth

The inoculum was prepared by adding       µl of 0.5 McFarland solution in       mL cation-adjusted Mueller Hinton broth (CAMHB).

What was the expected inoculum size?       \*       ^       CFU/mL (indicate for example 5 times 10 to the power of 5 using this format ‘5 \* 10 ^ 5’)

Comments or additional information:

**TEST FORM - *Campylobacter***

Which method did you use for antimicrobial susceptibility testing of *Campylobacter* in this EQAS?

 [ ]  MIC - Broth microdilution

Which standard(s)/guideline(s) did you use when performing AST?

 [ ]  CLSI

 [ ]  EUCAST

 [ ]  ISO 20776-1:2019

 [ ]  TREK

Which incubation conditions did you use?

 [ ]  36-37ºC, 48 hours

 [ ]  42ºC, 24 hours

Which solvent was used for the preparation of the 0.5 McFarland solution

 [ ]  Water

 [ ]  Saline

 [ ]  Mueller Hinton broth

The inoculum was prepared by adding       µl of 0.5 McFarland solution in       mL cation-adjusted Mueller Hinton broth supplemented with lysed horse blood (CAMHB-LHB).

What was the expected inoculum size?       \*       ^       CFU/mL (indicate for example 5 times 10 to the power of 5 using this format ‘5 \* 10 ^ 5’)

Comments or additional information:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.1 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.1 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.2 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.2 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.3 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.3 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.4 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.4 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.5 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.5 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.6 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.6 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.7 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.7 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.8 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *E. coli*  EURL 2024 EC-19.8 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

#### **TEST FORM**

AST of reference strain *E. coli* ATCC 25922

|  |  |  |
| --- | --- | --- |
|  | Antimicrobial  | MIC-value (μg/ml) |
| 1st panel | Amikacin, AMI |       |
| Ampicillin, AMP  |       |
| Azithromycin, AZI |       |
| Cefotaxime, FOT |       |
| Ceftazidime, TAZ |       |
| Chloramphenicol, CHL |       |
| Ciprofloxacin, CIP |       |
| Colistin, COL |       |
| Gentamicin, GEN |       |
| Meropenem, MERO |       |
| Nalidixic acid, NAL |       |
| Sulfamethoxazole, SMX\* |       |
| Tetracycline, TET |       |
| Tigecycline, TGC |       |
| Trimethoprim, TMP |       |
| 2nd panel | Cefepime, FEP |       |
| Cefotaxime, FOT |       |
| Cefotaxime + clavulanic acid, F/C |       |
| Cefoxitin, FOX |       |
| Ceftazidime, TAZ |       |
| Ceftazidime+ clavulanic acid, T/C |       |
| Ertapenem, ETP |       |
| Imipenem, IMI |       |
| Meropenem, MERO |       |
| Temocillin, TRM |       |

\* for the testing of the *E. coli* ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 5).

AST of the EURL-AR Internal Quality Control (QC) strain *Acinetobacter baumannii* (2012-70-100-69)

|  |  |  |
| --- | --- | --- |
|  | Antimicrobial  | MIC-value (μg/ml) |
| 1st panel | Ampicillin, AMP  |       |
| Azithromycin, AZI |       |
| Cefotaxime, FOT |       |
| Ceftazidime, TAZ |       |
| Chloramphenicol, CHL |       |
| Ciprofloxacin, CIP |       |
| Colistin, COL |       |
| Gentamicin, GEN |       |
| Meropenem, MERO |       |
| Nalidixic acid, NAL |       |
| Sulfamethoxazole, SMX\* |       |
| Tetracycline, TET |       |
| Tigecycline, TGC |       |
| Trimethoprim, TMP |       |
| 2nd panel | Cefepime, FEP |       |
| Cefotaxime, FOT |       |
| Cefotaxime + clavulanic acid, F/C |       |
| Cefoxitin, FOX |       |
| Ceftazidime, TAZ |       |
| Ceftazidime+ clavulanic acid, T/C |       |
| Ertapenem, ETP |       |
| Imipenem, IMI |       |
| Meropenem, MERO |       |
| Temocillin, TRM |       |

\* Sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 5).

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.1 | Amikacin, AMI |       |       |       |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.1 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

#### Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.2 | Amikacin, AMI |       |       |  |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.2 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.3 | Amikacin, AMI |       |       |  |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.3 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.4 | Amikacin, AMI |       |       |  |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.4 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.5 | Amikacin, AMI |       |       |  |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.5 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.6 | Amikacin, AMI |       |       |  |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.6 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.7 | Amikacin, AMI |       |       |  |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.7 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

Comments:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.8 | Amikacin, AMI |       |       |  |
| Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol, section ‘3.3’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL 2024 S-19.8 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid, F/C |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid, T/C |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype | [ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype | [ ]  Other phenotype[ ]  Susceptible (to panel 2 antimicrobials) |

Comments:

#### **TEST FORM**

AST of reference strain *E. coli* ATCC 25922

|  |  |  |
| --- | --- | --- |
|  | Antimicrobial  | MIC-value (μg/ml) |
| 1st panel | Amikacin, AMI |       |
| Ampicillin, AMP  |       |
| Azithromycin, AZI |       |
| Cefotaxime, FOT |       |
| Ceftazidime, TAZ |       |
| Chloramphenicol, CHL |       |
| Ciprofloxacin, CIP |       |
| Colistin, COL |       |
| Gentamicin, GEN |       |
| Meropenem, MERO |       |
| Nalidixic acid, NAL |       |
| Sulfamethoxazole, SMX\* |       |
| Tetracycline, TET |       |
| Tigecycline, TGC |       |
| Trimethoprim, TMP |       |
| 2nd panel | Cefepime, FEP |       |
| Cefotaxime, FOT |       |
| Cefotaxime + clavulanic acid, F/C |       |
| Cefoxitin, FOX |       |
| Ceftazidime, TAZ |       |
| Ceftazidime+ clavulanic acid, T/C |       |
| Ertapenem, ETP |       |
| Imipenem, IMI |       |
| Meropenem, MERO |       |
| Temocillin, TRM |       |

\* for the testing of the *E. coli* ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3).

AST of the EURL-AR Internal Quality Control (QC) strain *Acinetobacter baumannii* (2012-70-100-69)

|  |  |  |
| --- | --- | --- |
|  | Antimicrobial  | MIC-value (μg/ml) |
| 1st panel | Ampicillin, AMP  |       |
| Azithromycin, AZI |       |
| Cefotaxime, FOT |       |
| Ceftazidime, TAZ |       |
| Chloramphenicol, CHL |       |
| Ciprofloxacin, CIP |       |
| Colistin, COL |       |
| Gentamicin, GEN |       |
| Meropenem, MERO |       |
| Nalidixic acid, NAL |       |
| Sulfamethoxazole, SMX\* |       |
| Tetracycline, TET |       |
| Tigecycline, TGC |       |
| Trimethoprim, TMP |       |
| 2nd panel | Cefepime, FEP |       |
| Cefotaxime, FOT |       |
| Cefotaxime + clavulanic acid, F/C |       |
| Cefoxitin, FOX |       |
| Ceftazidime, TAZ |       |
| Ceftazidime+ clavulanic acid, T/C |       |
| Ertapenem, ETP |       |
| Imipenem, IMI |       |
| Meropenem, MERO |       |
| Temocillin, TRM |       |

\* Sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3).

#### **TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Interpretation |
| MIC-value (μg/ml) | S / R |
| *Campylobacter*EURL 2024 C-19.1 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL 2024 C-19.2 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL 2024 C-19.3 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL 2024 C-19.4 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |

####

#### **TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Interpretation |
| MIC-value (μg/ml) | S / R |
| *Campylobacter*EURL 2024 C-19.5 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL 2024 C-19.6 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL 2024 C-19.7 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL 2024 C-19.8 [ ]  *C. jejuni* [ ]  *C. coli* | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |

#### **TEST FORM**

Susceptibility testing of *Campylobacter jejuni* reference strain ATCC 33560

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | MIC-value (μg/ml) |
| 36 °C/48 hours | 42 °C/24 hours |
| *C. jejuni* ATCC 33560 | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |

AST of the EURL-AR Internal Quality Control (QC) strain *Campylobacter coli* 215-QC-ETP

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | MIC-value (μg/ml) |
| 36 °C/48 hours | 42 °C/24 hours |
| *C. jejuni* ATCC 33560 | Chloramphenicol |       |       |
| Ciprofloxacin |       |       |
| Ertapenem |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Tetracycline |       |       |